| Aripiprazole extended release | Aripiprazole lauroxil | Flupentixol decanoate* | Fluphenazine decanoate | Haloperidol decanoate | Olanzapine pamoate | Paliperidone palmitate (4-week) | Paliperidone palmitate (12-week) | Paliperidone palmitate (6-month) | Pipotiazine palmitate* | Risperidone microspheres | Risperidone subcutaneous | Zuclopenthixol decanoate* | |
| Trade (brand) name | Abilify Maintena | Aristada | Fluanxol Depot (Canada) | Generic | Haldol Decanoate | Zyprexa Relprevv | Invega Sustenna | Invega Trinza | Invega Hafyera | Piportil L4 (Canada) | Risperdal Consta | Perseris | Clopixol Depot (Canada) |
| Generation | Second | Second | First | First | First | Second | Second | Second | Second | First | Second | Second | First |
| Injection interval | 4 weeks | 4 weeks (441, 662, 882 mg) 6 weeks (882 mg only) 8 weeks (1064 mg only) | 2 to 4 weeks | 2 to 4 weeks | 4 weeks | 2 to 4 weeks | 4 weeks | 12 weeks (3 months) | 6 months | 3 to 4 weeks | 2 weeks | 4 weeks | 2 to 4 weeks |
| Available dose strengths | 300 mg 400 mg | 441 mg 662 mg 675 mg (loading dose) 882 mg 1064 mg | 20 mg/mL 100 mg/mL (variable dose) | 25 mg/mL (variable dose) | 50 mg/mL 100 mg/mL (variable dose) | 210 mg 300 mg 405 mg | 39 mg 78 mg 117 mg 156 mg 234 mg | -- 273 mg 410 mg 546 mg 819 mg | 1092 mg 1560 mg | 25 mg/mL 50 mg/mL | 12.5 mg 25 mg 37.5 mg 50 mg | 90 mg 120 mg | 200 mg/mL (variable dose) |
| Dose range (adult)Δ | 200 to 400 mg | 441 to 1064 mg | 10 to 50 mg | 12.5 to 100 mg | 20 to 450 mg | 150 to 405 mg | 39 to 234 mg | 273 to 819 mg | 1092 to 1560 mg | 75 to 200 mg | 12.5 to 50 mg | 90 to 120 mg | 100 to 400 mg |
| Maximum recommended dose | 400 mg every 4 weeks | 882 mg every 4 weeks | 100 mg every 2 weeks | 100 mg every 2 weeks | 450 mg every 4 weeks | 300 mg every 2 weeks | 234 mg every 4 weeks | 819 mg every 12 weeks | 1560 mg every 6 months | 250 mg every 3 weeks | 50 mg every 2 weeks | 120 mg every 4 weeks | 600 mg every 2 weeks |
| Conversion from oral tablets | Initiate LAI with single dose of 400 mg injection and continue overlap oral aripiprazole (or other antipsychotic) for 14 days. Concurrent with first dose. OR Alternative dosing (Canadian product label)¶: Two separate injections of 400 mg (at different sites) on the same day with a single dose of 20 mg oral aripiprazole given concurrent to injection. | If stable on oral 10 mg daily, then 441 mg LAI every 4 weeks. If stable on oral 15 mg daily then 662 mg LAI every 4 weeks, or 882 mg LAI every 6 weeks, or 1064 mg LAI every 8 weeks. If stable on oral ≥20 mg daily, then 882 mg LAI every 4 weeks. Oral aripiprazole should be continued for 21 days after the first dose of LAI. | Initiate LAI at 4 times daily oral dose every 2 weeks or 8 times daily oral dose every 4 weeks. For first week, overlap with oral treatment. | 1 mg of oral daily approximately 1.25 mg LAI every 3 weeks. | Initiate LAI at 10 to 20 times daily oral dose, up to 100 mg. If initial conversion requires >100 mg, follow by balance in 3 to 7 days. Then administer at 4-week intervals. The need for overlap with oral therapy varies based on initial LAI dose selected and clinical response; refer to UpToDate text. | If stable on oral 10 mg daily, then 210 mg LAI every 2 weeks or 405 mg LAI every 4 weeks for first 8 weeks, then 150 mg IM LAI every 2 weeks or 300 mg every 4 weeks. If stable on oral 15 mg daily, then 300 mg LAI every 2 weeks for first 8 weeks, then 210 mg LAI every 2 weeks or 405 mg LAI every 4 weeks. If stable on oral 20 mg daily, then 300 mg LAI every 2 weeks. | Conversion from oral extended release:
| Conversion from oral tablets is not available. Conversions from various doses of paliperidone palmitate 4-week LAI, once it has been established as adequate treatment, are shown in the footnote.◊ | Conversion from oral tablets is not available. Conversions from various doses of paliperidone palmitate 4-week LAI or paliperidone palmitate 12-week LAI, once established as adequate treatment, are shown in the footnote.§ | Discontinue oral treatment. Initiate at 50 to 100 mg LAI every 3 weeks. Individualize dose and interval in 25 mg increments based on response no more frequently than every 2 to 3 weeks. | If stable on ≤3 mg daily, then 25 mg every 2 weeks. If stable on >3 to ≤5 mg daily, then 37.5 mg every 2 weeks. If stable on >5 mg daily, then 50 mg every 2 weeks. For the first 3 weeks, overlap with full-dose oral treatment. | If stable on 3 mg daily, then initiate 90 mg monthly. If stable on 4 mg daily, then initiate 120 mg monthly. | If stable on oral dose up to 20 mg daily, then 100 mg LAI every 2 weeks. If stable on 25 to 40 mg oral daily, then 200 mg LAI every 2 weeks. If stable on 50 to 75 mg oral daily, then 300 mg LAI every 2 weeks. If stable on more than 75 mg daily, then 400 mg LAI every 2 weeks. |
| Injection site | Deltoid or gluteal | Deltoid (441 and 675 mg only) Gluteal (441, 662, 675, 882, or 1064 mg) | Gluteal or lateral thigh¥ | Gluteal‡ | Gluteal‡ | Gluteal only | Deltoid only (load) Deltoid or gluteal (maintenance) | Deltoid or gluteal | Gluteal | Gluteal | Deltoid or gluteal | Abdomen | Gluteal or lateral thigh¥ |
| Injection technique | Standard | Standard | Z-Track | Z-Track | Z-Track | Standard | Standard | Standard | Standard | Z-Track | Standard | Subcutaneous | Z-Track |
| Solubilization and vehicle | Low solubility particles in aqueous suspension | Low solubility particles in aqueous suspension | Ester in medium chain triglycerides or coconut oil | Ester in sesame seed oil | Ester in sesame seed oil | Nanoparticles in aqueous suspension | Nanoparticles in aqueous suspension | Nanoparticles in aqueous suspension | Low solubility particles in aqueous suspension | Ester in sesame seed oil | Microsphere matrix in aqueous suspension | Suspended in polymer solution | Ester in low viscosity vegetable oil |
